Cambridge researchers are developing implants to help repair brain pathways damaged by Parkinson’s disease. As part of a £69 ...

Parkinson’s disease is a neurodegenerative disease that causes nerve cells in the brain to die leading to impaired movement, ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Dec. 18, 2024 — Dancing lowers the depression associated with Parkinson's disease, and the benefits can be seen in multiple ways, a new study ... Nov. 19, 2024 — A recently published study ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

In a recent study, talk therapy in Parkinson’s disease led to significant improvement in patients' well-being, ...

Fingernail-sized vibrating gadgets, similar to the tiny devices that make your cellphone buzz, could help people with ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

“Parkinson’s is a progressive disease. It’s not something you can stabilize. It affects different parts of the body and it’s affected his legs,” she added. “But his voice is as good as ...

Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...